Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 7:25 AM ET

Biotechnology

Company Overview of Nerium Biotechnology, Inc.

Company Overview

Nerium Biotechnology, Inc. researches and develops oleander-based products for the treatment of certain forms of proliferative diseases and viral infections. Its lead product includes Anvirzel, which is used to treat various forms of cancer. The company’s product line also comprises HIviral for the treatment of HIV/AIDS; HEP-viral for the treatment of hepatitis C; and NeriumAD, a skin cream for age-defying treatment. Nerium Biotechnology, Inc. was incorporated in 2006 and is headquartered in Toronto, Canada.

500-220 Bay Street

Toronto, ON M5J 2W4

Canada

Founded in 2006

Phone:

416-862-7330

Fax:

416-363-1813

Key Executives for Nerium Biotechnology, Inc.

Chairman, Chief Executive Officer and President
Age: 64
Chief Financial Officer, Vice President of Operations, Secretary and Treasurer
Age: 58
Compensation as of Fiscal Year 2015.

Nerium Biotechnology, Inc. Key Developments

Nerium Biotechnology, Inc, Annual General Meeting, Jun 26, 2015

Nerium Biotechnology, Inc, Annual General Meeting, Jun 26, 2015., at 10:00 US Eastern Standard Time. Location: Law offices of Stikeman Keeley Spiegel Pasternack LLP. Agenda: To receive the audited consolidated financial statements of the Company for the year ended December 31, 2014, together with the report of the auditors thereon; to elect directors of the Company for the ensuing year; to re-appoint auditors and to authorize the directors to fix their remuneration; to consider and, if thought advisable, pass an ordinary resolution, with or without variation, to adopt a Shareholders Rights Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment or adjournments thereof.

Nerium Biotechnology, Inc. Restates Income for the Three-Month and Nine-Month Periods Ended September 30, 2013; Year Ended December 31, 2013, Three-Month Period Ended March 31, 2014 and Three-Month and Six-Month Periods Ended June 30, 2014

Nerium Biotechnology Inc. announced that, due to a mathematical formula error in its equity investment calculations, it has restated its comprehensive income for the three-month and nine-month periods ended September 30, 2013, the year ended December 31, 2013 the three-month period ended March 31, 2014 and the three-month and six-month periods ended June 30, 2014. For the nine months ended September 30, 2013, Comprehensive income was $10,029,323 or $0.28 per basic and diluted share compared to $9,033,458 or $0.25 per basic and diluted share as previously reported. For the three months ended September 30, 2013, Comprehensive income was $4,400,434 or $0.12 per basic and diluted share compared to $3,404,569 or $0.09 per basic and diluted share as previously reported. For the year ended December 31, 2013, Comprehensive income was $12,633,906 or $0.35 per basic share and or $0.34 per diluted share compared to $9,747,156 or $0.27 per basic and diluted share as previously reported. For the three-month period ended March 31, 2014, Comprehensive income was $4,952,698 or $0.14 per basic share and or $0.13 per diluted share compared to $5,589,650 or $0.15 per basic share and or $0.14 per diluted share as previously reported. For the six-month period ended June 30, 2014, Comprehensive income was $11,939,031 or $0.33 per basic share and or $0.31 per diluted share compared to $12,365,706 or $0.34 per basic share and or $0.32 per diluted share as previously reported. For the three-month period ended June 30, 2014, Comprehensive income was $6,936,333 or $0.19 per basic share and or $0.18 per diluted share compared to $6,826,055 or $0.19 per basic share and or $0.18 per diluted share as previously reported.

Nerium Biotechnology, Inc Appoints Richard Boxer as Director

Nerium Biotechnology Inc. announced that its Board of Directors has met and made the following resolutions, Mr. Richard Boxer of Toronto, Canada has been appointed as a director of NBI and the number of directors has been increased from six to seven. Mr. Boxer has extensive experience with business and community organizations in both the "for profit" and "not for profit" sectors and has served in numerous capacities on various boards and committees.

Similar Private Companies By Industry

Company Name Region
Targanta Therapeutics, Inc. Americas
Induce Biologics Inc. Americas
PerkinElmer BioSignal, Inc. Americas
Portable Health Intelligence Inc. Americas
Capital 21 Holdings Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nerium Biotechnology, Inc., please visit www.neriumbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.